Orphazyme A/S (ORPH)

4.830
-0.270(-5.29%)
  • Volume:
    1,037,588
  • Bid/Ask:
    4.820/4.850
  • Day's Range:
    4.790 - 5.160

ORPH Overview

Prev. Close
5.1
Day's Range
4.79-5.16
Revenue
-
Open
5.15
52 wk Range
4.75-77.06
EPS
-
Volume
1,037,588
Market Cap
177.95M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
11,969,382
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
34,952,241
Next Earnings Date
23 Aug 2021
What is your sentiment on Orphazyme A/S?
or
Vote to see community's results!

Orphazyme A/S News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellNeutral
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Orphazyme A/S Company Profile

Orphazyme A/S Company Profile

Employees
141
Market
Denmark

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Read More
  • Is there anything positive going to happen with ORPH in the cery near future?
    0
    • I doubt it.. Looks like the short squeeze is over!
      0
  • 80% chance that FDA will approve it tonight.
    1
    • fda need more data down 74% atm
      0
    • FDA disapproved
      0
  • again see something going to happen
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.